1. AB0243 Data on the Impact of Anti-Cyclic-Citrulinnated Peptide Antibody Status (ANTI-CCP) on the Management of Patients with Early Rheumatoid Arthritis. (10th June 2014) Authors: Ratnik, K.; Baranauskaite, A.; Iancuta, I.; Vlak, T.; Poόr, G.; Kuzminiene, R. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 884 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0659 SECUKINUMAB PROVIDES SIGNIFICANT IMPROVEMENT OF SPINAL PAIN IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE 24-WEEK PHASE 3 SKIPPAIN STUDY. (2nd June 2020) Authors: Poddubnyy, D.; Pournara, E.; Zielińska, A.; Baranauskaite, A.; Muñoz Jimenez., A.; Kumari, P.; Schulz, B.; Rissler, M.; Perella, C.; Marzo-Ortega, H. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 1624 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0670 Prevalence of chronic back pain and inflammatory back pain in cohort young lithuanian people. (23rd January 2014) Authors: Sabaliauskiene, J.; Baranauskaite, A. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A993 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. AB0805 Concordance between Clinical Findings and Ultrasound in Gout. (15th July 2016) Authors: Norkuviene, E.; Petraitis, M.; Apanaviciene, I.; Virviciute, D.; Baranauskaite, A. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 1179 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. AB0918 Ultrasonographic Changes in the Early Gout: Pooled Results From the Prospective Controlled Study. (9th June 2015) Authors: Norkuviene, E.; Petraitis, M.; Apanaviciene, I.; Baranauskaite, A. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 1207 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. AB1087 Musculoskeletal Ultrasound as A Tool (MUST) in Routine Rheumatology Practice: Data from Central and Eastern European Countries. (10th June 2014) Authors: Mandl, P.; Baranauskaite, A.; Damjanov, N.; Kurucz, R.; Nagy, O.; Nemec, P.; Peric, P.; Petranova, T.; Pille, A.; Rednic, S.; Vlad, V.; Zlnay, M.; Balint, P.V. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 1161 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. FRI0128 A Phase III Randomised, Double-Blind Clinical Study Comparing SB4, An Etanercept Biosimilar, With Etanercept Reference Product (Enbrel®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-Week Results). (9th June 2015) Authors: Vencovský, J.; Sylwestrzak, A.; Leszczyński, P.; Porawska, W.; Baranauskaite, A.; Tseluyko, V.; Zhdan, V.; Stasiuk, B.; Milasiene, R.; Barrera Rodriguez, A.A.; Cheong, S.Y.; Ghil, J.; Emery, P. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 467 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. FRI0161 Sustained Efficacy and Comparable Safety and Immunogenicity after Transition To SB5 (An Adalimumab Biosimilar) vs Continuation of The Adalimumab Reference Product in Patients with Rheumatoid Arthritis: Result of Phase III Study. (15th July 2016) Authors: Weinblatt, M.; Baranauskaite, A.; Niebrzydowski, J.; Dokoupilova, E.; Zielinska, A.; Sitek-Ziolkowska, K.; Jaworski, J.; Racewicz, A.; Pileckyte, M.; Jedrychowicz-Rosiak, K.; Zhdan, V.; Cheong, S.Y.; Ghil, J. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 487 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. FRI0162 Comparable Safety and Immunogenicity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product in Patients with Rheumatoid Arthritis: Results of Phase III Transition Study. (15th July 2016) Authors: Smolen, J.S.; Choe, J.-Y.; Prodanovic, N.; Niebrzydowski, J.; Staykov, I.; Dokoupilova, E.; Baranauskaite, A.; Yatsyshyn, R.; Mekic, M.; Porawska, W.; Ciferska, H.; Jedrychowicz-Rosiak, K.; Zielinska, A.; Choi, J.; Rho, Y.H. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 488 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. FRI0164 Local tuberculosis incidence affects the rate of positive conversion in the quantiferon®-tb gold test among patients receiving infliximab or ct-p13 therapy. (23rd January 2014) Authors: Yoo, D. H.; Shevchuk, S.; Ramiterre, E.; Kovalenko, V.; Tee, M.; Tobias Arteaga, E.; Morales Olazabal, L.; Baranauskaite, A.; Bukauskiene, L.; Lim, M. J.; Lee, Y.-A.; Rednic, S.; Ahn, C.; Kim, H.; Park, W. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A426 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗